Inhibikase Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $260,501 | $123,440 | $3.1M |
| Operating income | -$52.0M | -$28.6M | -$20.1M | -$18.1M | -$14.8M |
| Cash from operations | -$27.8M | -$19.1M | -$18.1M | -$17.4M | -$14.3M |
| Capital expenditure | $13,399 | $0 | $14,238 | $243,255 | $0 |
| Free cash flow | -$27.8M | -$19.1M | -$18.1M | -$17.6M | -$14.3M |
| Total assets | $181.2M | $98.6M | $14.5M | $24.9M | $42.5M |
| Total liabilities | $8.3M | $3.7M | $3.5M | $3.9M | $4.1M |
Shares outstanding 132.0M · Free float 81.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.